David S. Ettinger
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 153
- Lung Cancer Research Studies 74
- Cancer Treatment and Pharmacology 33
- Cancer Immunotherapy and Biomarkers 22
- Colorectal Cancer Treatments and Studies 15
-
- Lung Cancer Treatments and Mutations 85
- Lung Cancer Diagnosis and Treatment 49
- Co-authors
- Alexander Spira (3 shared papers)Eric Keith Rowinsky (16 shared papers)John C. Ruckdeschel (7 shared papers)Dianne M. Finkelstein (7 shared papers)Martin D. Abeloff (27 shared papers)L B Grochow (12 shared papers)Ross C. Donehower (23 shared papers)Susan E. Sartorius (9 shared papers)
- Journals
- Journal of the National Comprehensive Cancer Network (42 papers)Journal of Clinical Oncology (25 papers)Cancer (20 papers)International Journal of Radiation Oncology*Biology*Physics (19 papers)Lung Cancer (11 papers)
- Partner nations
- United StatesIndiaCanada
In The Last Decade
David S. Ettinger
297 papers receiving 21.8k citations
David S. Ettinger's Hit Papers
Peers
Comparison fields: 5 of 166
- Oncology 8.4k
- Pulmonary and Respiratory Medicine 9.4k
- Cancer Research 1.9k
- Gastroenterology 542
- Radiology, Nuclear Medicine and Imaging 1.8k
Countries citing papers authored by David S. Ettinger
This map shows the geographic impact of David S. Ettinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Ettinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Ettinger more than expected).
Fields of papers citing papers by David S. Ettinger
This network shows the impact of papers produced by David S. Ettinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Ettinger. The network helps show where David S. Ettinger may publish in the future.
Co-authors
The 25 scholars most cited alongside David S. Ettinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 299 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2017 | 1114 |
| 2 | Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2022 | 1007 |
| 3 | Multidisciplinary Management of Lung Cancer Hit paper breakdown → | 2004 | 761 |
| 4 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 Hit paper breakdown → | 2021 | 756 |
| 5 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020 Hit paper breakdown → | 2019 | 722 |
| 6 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 Hit paper breakdown → | 2016 | 622 |
| 7 | American Cancer Society lung cancer screening guidelines Hit paper breakdown → | 2013 | 614 |
| 8 | Non–Small Cell Lung Cancer Hit paper breakdown → | 2010 | 598 |
| 9 | NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines Hit paper breakdown → | 2007 | 503 |
| 10 | Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2018 | 477 |
| 11 | Non–Small Cell Lung Cancer, Version 4.2024 Hit paper breakdown → | 2024 | 423 |
| 12 | 2015 | 416 | |
| 13 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 Hit paper breakdown → | 2018 | 402 |
| 14 | 1991 | 384 | |
| 15 | Non–Small Cell Lung Cancer, Version 2.2013 Hit paper breakdown → | 2013 | 382 |
| 16 | Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer Hit paper breakdown → | 2020 | 376 |
| 17 | 2018 | 343 | |
| 18 | NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023 Hit paper breakdown → | 2023 | 339 |
| 19 | 1992 | 321 | |
| 20 | 1993 | 321 |
About David S. Ettinger
David S. Ettinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 299 papers that have together received 22.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (85 papers), Lung Cancer Research Studies (74 papers), Lung Cancer Diagnosis and Treatment (49 papers), Neuroendocrine Tumor Research Advances (34 papers), Cancer Treatment and Pharmacology (33 papers), Cancer therapeutics and mechanisms (27 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Colorectal Cancer Treatments and Studies (15 papers). The work is most often cited by research in Oncology (8.4k citations), Pulmonary and Respiratory Medicine (9.4k citations), Cancer Research (1.9k citations), Gastroenterology (542 citations) and Radiology, Nuclear Medicine and Imaging (1.8k citations). David S. Ettinger has collaborated with scholars based in United States, India and Canada. Frequent co-authors include Alexander Spira, Eric Keith Rowinsky, John C. Ruckdeschel, Dianne M. Finkelstein, Martin D. Abeloff, L B Grochow, Ross C. Donehower, Susan E. Sartorius, Arlene A. Forastiere and R E Gregory. Their work appears in journals such as Journal of the National Comprehensive Cancer Network, Journal of Clinical Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.